Orforglipron
Also known as: LY3502970, Oral non-peptide GLP-1 receptor agonist
limited human dataNot FDA approvedResearch only
Published Dose Range
Low12 mg/day
Typical24-36 mg/day
High45 mg/day
Phase 3 ATTAIN-1 obesity trial uses dose-escalation up to 36 mg daily. Oral, non-peptide structure unlike injectable GLP-1 analogs.
Published Cycle Range
No published cycle data available.
Administration
Routesoral
FrequencyOnce daily
Preferred timingSame time each day, with or without food
Unlike oral semaglutide, no fasting/water-volume restrictions because the molecule is not a peptide.
Safety Profile
Contraindications
- • Personal or family history of medullary thyroid carcinoma (class label)
Common side effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Constipation
- • Decreased appetite
Serious risks
- • Pancreatitis risk (class effect)
- • Thyroid C-cell tumor risk (class effect, animal data)
Drug interactions
- • Insulin
- • Sulfonylureas
Requires monitoring
- • Blood glucose
- • Heart rate
Pregnancy / breastfeeding
Avoid — limited human data
Common Misconceptions
- Not a peptide — small-molecule oral GLP-1 agonist with predictable absorption
- Not yet approved — investigational only as of 2026
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.